PARIS, May 19, 2011 /PRNewswire/ — OrbusNeich announced that
data from multiple clinical trials supporting the safety and
efficacy of the Genous Stent in cases where prolonged dual
antiplatelet therapy (DAPT) is not advisable were featured today
during the HEALING Symposium titled “How to assess and treat
patients who are not suitable candidates for prolonged dual
antiplatelet therapy” at EuroPCR 2011 in Paris.
Presenters discussed current treatment alternatives to drug
eluting stents (DES) for patients who are contraindicated for
prolonged DAPT and the benefits of the Genous endothelial
progenitor cell (EPC) capture technology for addressing these
challenging cases. The symposium also explored the potential
for new imaging tools to assess stent apposition and arterial
healing in a clinical setting.
Robbert de Winter, M.D., Ph.D., of the Academic Medical Center,
Amsterdam, presented three-year follow-up data that demonstrated
the safety and efficacy of the Genous Stent in a large real-world
patient population with mostly complex lesions and estimated high
risk for restenosis. At three years, the definite stent thrombosis
(ST) in 405 unselected patients treated with the Genous Stent was
0.5%, which was unchanged from one year, and there was a probable
ST in one patient, which increased the rate of probable ST to 1.0%
at three years compared to 0.8% at one year. In addition, the
target lesion revascularization (TLR) rate at three years was 14.2%
versus 10.6% at one year.
“These long-term data show no additional cases of definite stent
thrombosis between one and three years attests to the durability
and excellent safety profile of the Genous Stent,” said Prof. de
Winter.
Jonathan Hill, M.D., of King’s College Hospital in London
discussed the need to modify practices with an awareness of
bleeding risk. He defined the predictors of high risk for
bleeding to be age (>80), a previous bleeding episode, gender
(female), renal in
‘/>”/>
